Low-dose versus standard-dose anticoagulation with argatroban or enoxaparin during extracorporeal membrane oxygenation controlled by anti-IIa or anti-Xa assay

Brief summary (registry, in English)

Description of the efficacy and safety of low dose (LD) and standard dose (SD) anticoagulation with argatroban and enoxaparin in patients on ECMO support.

What you commit to

• Study type: Interventional · Phase 2
• Planned participants: 200
• 2 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who are on ECMO (a machine that supports the heart and lungs) and receive argatroban or enoxaparin to prevent blood clots.

Age

18 years or older

Sex

Women and men can join.

Earlier treatment

People must be on ECMO support with argatroban or enoxaparin anticoagulation.

Main reasons for not taking part

• Included in the lung transplant program at Motol Hospital
• Known hypersensitivity to components of the investigational medicinal products
• Allergic reaction to the active substances of the investigational medicinal products
• Pregnancy
• Breastfeeding

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (2)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details